4Filed Jul 22, 8:00 PM ET
Rani Therapeutics (RANI) 10% Owner Imran Mir A Buys 36,000 Shares
$RANI · Rani Therapeutics Holdings, Inc.Research Summary
AI-generated summary of this SEC filing
Rani Therapeutics (RANI) 10% Owner Imran Mir A Buys 36,000 Shares
What Happened
Imran Mir A, a reported 10% owner of Rani Therapeutics, purchased 36,000 shares on July 21, 2026, in open-market transactions. The filing reports a weighted-average price of $0.69 per share (range $0.688–$0.69), for a total purchase cost of approximately $24,840. This was a purchase (often viewed as a bullish signal compared with a sale), though the stake size is modest.
Key Details
- Transaction date: July 21, 2026 (filed on July 23, 2026). Filing appears to be within the standard two-business-day Form 4 window.
- Transaction type/code: Open-market purchase (P).
- Price: Weighted-average $0.69; per-footnote prices ranged from $0.688 to $0.69. The filer offers to provide a breakdown on request.
- Shares purchased: 36,000; total value ≈ $24,840.
- Shares owned after transaction: The filing does not state a post-transaction total for the purchased shares. Footnotes report existing holdings attributable to entities the reporting person is affiliated with (see below).
- Notable footnotes:
- F1: Price is a weighted average across multiple trades ($0.688–$0.69); full breakdown available on request.
- F2: Reporting person is General Partner of InCube Ventures II, L.P.; InCube Labs, LLC is wholly owned by the reporting person/family. Footnote lists 52,781, 13,664 and 7,694 Class A shares held by related entities (total 74,139 Class A shares held via entities); the reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
- F3: Footnote lists 22,411,124 and 248,929 Class B shares held by related entities (total 22,660,053 Class B shares); similar disclaimer of beneficial ownership.
Context
- The filer is a 10% owner and a general partner of investment entities, so these holdings are largely through affiliated vehicles rather than direct executive compensation.
- The purchase amount is relatively small (~$25k), so while purchases receive attention, this transaction alone may be routine.
- No options exercise, awards, or gifts are reported in this transaction.